JSKN016 + ivonescimab

JSKN016 + ivonescimab is an investigational combination therapy studied for the treatment of advanced non-small cell lung cancer (NSCLC). JSKN016 is an experimental agent for which detailed mechanistic and compositional information is not publicly disclosed, and is being evaluated in multi-agent regimens that also include ivonescimab. Ivonescimab is a first-in-class, bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), integrating immunotherapy and anti-angiogenesis mechanisms. The combination of ivonescimab with chemotherapy has shown statistically significant improvements in progression-free survival and overall survival in phase III clinical trials for various NSCLC populations, including those with EGFR-mutations post-tyrosine kinase inhibitor (TKI) therapy[1][2][3][5][9]. JSKN016 + ivonescimab is being evaluated in a phase I clinical trial for advanced NSCLC, with primary outcomes relating to safety and therapeutic effect[4].